Viskase Holdings, Inc.

VISK ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $683.0K
Depreciation & Amortization $6.9M
Depreciation —
Amortization —
Stock-Based Compensation $7.9M
Net Cash from Operating Activities $15.0M
Investing Activities
Capital Expenditures $2.0M
Business Acquisitions —
Net Cash from Investing Activities $-26.1M
Financing Activities
Dividends Paid —
Stock Repurchases $2.0M
Net Cash from Financing Activities $-18.1M
Net Change in Cash $-29.3M
Free Cash Flow $13.0M
← Newer Page 3 of 3 Older →